Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
頻尿,残尿感などの膀胱刺激症状を主訴とし,器質的疾患のない神経性頻尿患者23例にベンゾジアゼピン系の抗不安薬であるアルプラゾラムを投与し,その臨床的効果を検討した。アルプラゾラム投与後の昼間排尿回数は投与2週間後,4週問後ともに統計学的に有意に減少した(それぞれp=0.0007およびp<0.0001)。夜間排尿回数は4週間後で有意の減少がみられた(p=0.OOO2)。また,残尿感,尿意切迫感を含めた膀胱刺激症状全般に対する効果は有効率87.0%であり,患者満足度も87.0%であった。投与を中断するような副作用は1例もなく,アルプラゾラムは神経性頻尿に対して有効な薬剤と考えられた。
The clinical effects of alprazolam, a benzodiazepine anti-anxiety drug, were studied in 23 patients with psychogenic pollakisuria complaining of pollakisuria and/or sensation of residual urine. Diurnal urinary frequency decreased after 2 and 4 weeks and decreased rates were statistically sig-nificant (p=0.0007 and p<0.0001 respectively). Nocturnal urinary frequency also statistically decreased after 4 weeks. The overall efficacy rate for irritative bladder symptom, and rate of patients satisfaction, was 87.0%, and no serious side effects were observed. Alprazolam was considered to be effective in psychogenic pollakisuria.
Copyright © 1998, Igaku-Shoin Ltd. All rights reserved.